1) Describe the biological diagnosis and staging criteria for Alzheimer's disease and available biomarker testing

  2) Evaluate potential risks and benefits associated with biomarker testing in predementia populations

  3) Assess current evidence on psychosocial and behavioral outcomes of biomarker testing in asymptomatic and symptomatic populations